Evidence map›Paper›PMID 40288458›Full record

ArticleJournal of affective disorders2025

Baseline perceived stress as a predictor of ketamine/esketamine treatment response in treatment-resistant depression.

Stefanie Cavalcanti, Vanessa K Pazdernik, Jennifer L Vande Voort, Simon Kung, Balwinder Singh

Abstract read
In one paragraph

Article in Journal of affective disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Stefanie CavalcantiDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States of America.
Vanessa K PazdernikDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States of America.
Jennifer L Vande VoortDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States of America.
Simon KungDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States of America.
Balwinder SinghDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States of America. Electronic address: singh.balwinder@mayo.edu.

Funding

Institutional Career Development CoreKL2TR002379 · NCATS · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2017 to 2026
$14.9M
NCATS NIH HHS KL2 TR002379
6 · The paper itself

Abstract

backgroundChronic stress is a risk factor for depression and may contribute to treatment resistance. This historical cohort study examined the association between baseline perceived stress, measured with the Perceived Stress Scale (PSS), and response to (es) ketamine in treatment-resistant depression (TRD).

methodAdult TRD patients who received intravenous racemic ketamine or intranasal esketamine were included. Depression symptoms were evaluated using the Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR). Baseline stress was assessed using the PSS, with scores categorized into low to moderate (PSS < 27) and high (PSS ≥ 27) stress. Statistical tests, including Pearson correlation, Fisher's exact test, and Kruskal-Wallis tests, were used to explore associations between baseline stress, remission (QIDS-SR ≤ 5), and the number of treatments required for remission. Firth's logistic regression model estimated odds ratios (ORs) and 95 % confidence interval (CI).

resultsAmong 39 patients (median age 47, 61.5 % female), 66.7 % had high perceived stress. Patients with high PSS scores required more treatments for remission (median = 3 vs. 1, p = 0.04). Each 5-point PSS increase reduced remission odds by 60 % (OR = 0.40, 95 % CI: 0.14-0.81, p = 0.009), adjusting for stimulant use. Notably, these effects were independent of baseline depression severity. LIMITATIONS: The study's observational design and lack of a placebo group limit the findings.

conclusionsTRD patients with high baseline perceived stress had lower odds of remission, and required more treatments to achieve remission. Further research should investigate whether stress-reduction strategies combined with ketamine could enhance treatment outcomes and whether responses differ between acute and chronic perceived stress.

Indexed as

Antidepressive AgentsDepressive Disorder, Treatment-ResistantKetamineStress, PsychologicalAdministration, IntranasalAdultCohort StudiesFemaleHumansMaleMiddle AgedTreatment OutcomeAntidepressive AgentsEsketamineKetamineExcitatory amino acid antagonistsKetamineMood disordersStress

Identifiers

PMID40288458
PMCPMC12087936

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.